Citi Raises PT on Pfizer Inc. (PFE) to $26; Maintains 'Neutral' Rating

With strong hedge fund interest and a low price-to-earnings ratio, Pfizer Inc. (NYSE:PFE) secures a place on our list of the 10 Most Undervalued Value Stocks to Buy Now.

Following the company’s strong Q2 performance, Citi raised its price target on Pfizer Inc. (NYSE:PFE) from $25 to $26 on August 6, 2025, maintaining a ‘Neutral’ rating. The analyst attributed the target revision to strong results. At the same time, Citi advised caution regarding continued policy uncertainties.

Pfizer Inc. (NYSE:PFE) reported 10% revenue growth, taking total revenue to $14.7 billion. The top-line growth was driven by strong sales of the Vyndaqel product family, Comirnaty, Paxlovid, Padcev, Eliquis, and other products. At the quarter-end, the company also reiterated its 2025 revenue guidance of $61.0-$64.0 billion, while raising its adjusted diluted EPS outlook by $0.10 at the midpoint to $2.90-$3.10. This guidance raise was made despite challenges caused by the Inflation Reduction Act’s Medicare Part D redesign.

Pfizer Inc. (NYSE:PFE) discovers, develops, and markets biopharmaceutical products globally. It is included in our list of the most undervalued value stocks to buy.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Gold Penny Stocks to Buy According to Hedge Funds and 11 Best Rebound Stocks to Buy According to Hedge Funds.

Disclosure: None.